Table 3.
Hazard ratios and five-year recurrence-free interval rates for omission vs receipt of radiotherapy for patient subgroups
| Characteristics | N | No. of events/Total No. of women |
HR (95% CI) | 5-year RFI rates, % |
|||
|---|---|---|---|---|---|---|---|
| No RT | RT | No RT | RT | Absolute differences, % (95% CI) | |||
| Overall* | 1778 | 53/373 | 91/1405 | 2.59 (1.38 to 4.89) | 93.5 | 97.9 | 4.4 (0.7 to 8.1) |
| Hormone status† | |||||||
| ER+ and PR+ | 1361 | 25/218 | 39/1143 | 2.47(0.92 to 6.68) | 94.5 | 98.0 | 3.5 (−1.3 to 8.3) |
| Other | 417 | 20/155 | 22/262 | 2.55 (1.15 to 5.66) | 92.0 | 97.7 | 5.7 (0.4 to 11.8) |
| Oncotype DX recurrence score‡ | |||||||
| 0-10 | 1120 | 10/161 | 16/959 | 2.39 (0.87 to 6.58) | 94.7 | 98.6 | 3.9 (−1.2 to 8.9) |
| 11-18 | 658 | 19/212 | 25/446 | 2.62 (1.10 to 6.28) | 92.0 | 97.3 | 5.3 (0.3 to 11.0) |
| Age Group, at random assignment/enrollment§ | |||||||
| <60 y | 903 | 17/130 | 42/773 | 2.45 (1.00 to 7.82) | 90.0 | 95.4 | 5.4 (2.9 to 13.7) |
| 60-70 y | 296 | 13/122 | 12/174 | 2.37 (0.89 to 10.35) | 93.4 | 98.4 | 5.0 (1.0 to 9.0) |
| >70 y | 579 | 14/121 | 6/458 | 1.99 (0.29 to 13.47) | 95.1 | 98.1 | 3.0 (−0.9 to 6.9) |
| Grade ‖ | |||||||
| Low | 439 | 6/98 | 9/341 | 2.33 (0.59 to 9.20) | 99.0 | 99.8 | 0.8 (−1.4 to 2.9) |
| Intermediate/High | 922 | 20/191 | 23/731 | 2.16 (0.90 to 5.18) | 91.6 | 96.1 | 4.5 (−1.9 to 10.9) |
| Tumor size¶ | |||||||
| ≤ 1 cm | 635 | 24/209 | 19/426 | 2.37 (1.07 to 5.26) | 92.8 | 96.4 | 3.6 (−1.6 to 8.7) |
| > 1 cm | 1143 | 20/164 | 42/979 | 2.74 (1.42 to 5.32) | 92.0 | 96.8 | 4.8 (−2.6 to 12.2) |
Cox models adjusted for patient age, tumor grade (low, moderate, high, or unknown), ER/PR status (ER+ and PR+ or other), HER2 (negative or unknown), initial hormonal treatment (tamoxifen, aromatase inhibitors or other), tumor size, trial, and Oncotype DX recurrence score. RFI rates evaluated at mean age, tumor size, Oncotype DX recurrence score, and tamoxifen hormonal treatment, low grade, ER+/ PR+ status and in studies where radiotherapy was randomized. RFI = recurrence-free interval; CI = confidence interval; HR = hazard ratio; RT = radiotherapy.
Cox models adjusted for patient age, tumor grade (low, moderate, high, or unknown), tumor size, trial type, and Oncotype DX recurrence score.
Cox models adjusted for patient age, tumor grade (low, moderate, high, or unknown), ER/PR status (ER+ and PR+ or other), tumor size, trial type, and Oncotype DX® recurrence score.
Cox models adjusted for patient age, tumor grade (low/moderate, high, or unknown), ER/PR status (ER+ and PR+ or other), tumor size, trial type and Oncotype DX® recurrence score.
Cox models adjusted for patient age, ER/PR status (ER+ and PR+ or other), tumor size, trial type, and Oncotype DX® recurrence score.
Cox models adjusted for patient age, ER/PR status (ER+ and PR+ or other), and Oncotype DX recurrence score.